Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab

被引：0
|
作者：
Ruessel, J. [1 ]
机构：
[1] Univ Klinikum Halle Saale, Klin Innere Med 4, D-06120 Halle, Saale, Germany
来源：
ONKOLOGE | 2015年 / 21卷 / 04期
关键词：
D O I：
10.1007/s00761-015-2919-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [1] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [2] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [3] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [4] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [5] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [6] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Spadi, Rosella
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17): : 1609 - 1618
  • [7] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] FOLFOXIRI and bevacizumab in metastatic colorectal cancer
    Rahman, Ahmadur
    [J]. LANCET ONCOLOGY, 2014, 15 (13): : E590 - E590
  • [9] FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Haines, Ian E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03): : 290 - 291
  • [10] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345